Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz
{"title":"奥帕他替尼治疗类风湿性关节炎及对传统合成改变病情抗风湿药反应不佳者：5年的疗效和安全性（SELECT-NEXT）。","authors":"Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz","doi":"10.3899/jrheum.2023-1062","DOIUrl":null,"url":null,"abstract":"To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).\",\"authors\":\"Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz\",\"doi\":\"10.3899/jrheum.2023-1062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT.\",\"PeriodicalId\":501812,\"journal\":{\"name\":\"The Journal of Rheumatology\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.2023-1062\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.2023-1062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
